Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.

Chen, Nianhang; Chawla, Sant P; Chiorean, Elena Gabriela; Read, William L; Gorbaty, Mayer; Mita, Alain C; Yung, Lotus; Bryan, Peter; McNally, Richard; Renschler, Markus F; Sharma, Sunil

Chen, Nianhang; Chawla, Sant P; Chiorean, Elena Gabriela; Read, William L; Gorbaty, Mayer; Mita, Alain C; Yung, Lotus; Bryan, Peter; McNally, Richard; Renschler, Markus F; Sharma, Sunil.

Affiliation

Chen N; Celgene Corporation, 86 Morris Avenue I-212C, Summit, NJ 07901, USA. nchen@celgene.com

Cancer Chemother Pharmacol ; 71(4): 1083-94, 2013 Apr.

Article in En | MEDLINE | ID: mdl-23400695

Subject(s)

Anthracyclines/pharmacokinetics; Antineoplastic Agents/pharmacokinetics; Heart/drug effects; Neoplasms/drug therapy; Adult; Aged; Anthracyclines/adverse effects; Anthracyclines/pharmacology; Electrocardiography/drug effects; Female; Heart/physiology; Heart Rate/drug effects; Humans; Male; Middle Aged; NAD(P)H Dehydrogenase (Quinone)/genetics

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Anthracyclines / Heart / Neoplasms / Antineoplastic Agents Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2013 Document type: Article Affiliation country: United States Country of publication: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google